跳到正文
原文
bioRxiv 预印本· Yegodayev, K. M., Perelman, G., Shami, T., Kaufman, B., Raviv, D., Marripati, D., Khateeb, A., Ben-uri, R., Levi Galibov, O., Milo, I., Raizman, A., Veinblat, A., Nissani, A., Zuri, N., Babu Manikandan, D., Rudnitsky, E., Novoplansky, O., Zorea, J., Eisdorfer, S. A., Jagadeeshan, S., Ezri, G., Waidha, K., Abu Shareb, R., Wainer, M., Hadad, U., Itzhaki, O., Shapira-Frommer, R., Wolf, Y., Cohen, M., Kong, D., Wang, H., Porgador, A., Keren, L., Aharoni, A., Carmi, Y., Cohen, O., Elkabets, M. ·· 21 天前AI 评分38

靶向PD-1与AXL的四价双特异性抗体BiTE-AXL/PD-1可重塑肿瘤微环境并克服抗PD-1耐药

Spatially enforced engagement of PD-1⁺ T cells with AXL⁺ cells reprograms the tumor microenvironment and overcomes anti-PD-1 resistance

AI 导读

研究者开发了同时结合PD-1与AXL的非串联四价IgG双特异性抗体BiTE-AXL/PD-1,在体外增强T细胞活化与AXL依赖性肿瘤细胞杀伤,效果优于抗AXL与抗PD-1单抗联用。

来源:bioRxiv 预印本 · biorxiv.org